| 0.02 0 (0%) | 11-25 15:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.03 | 1-year : | 0.03 |
| Resists | First : | 0.02 | Second : | 0.03 |
| Pivot price | 0.02 |
|||
| Supports | First : | 0.02 | Second : | 0.02 |
| MAs | MA(5) : | 0.02 | MA(20) : | 0.02  |
| MA(100) : | 0.13 |
MA(250) : | 0.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 55.3 |
D(3) : | 49.7 |
| RSI | RSI(14): 32.8 | |||
| 52-week | High : | 0.55 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HSTO ] has closed below upper band by 45.7%. Bollinger Bands are 94.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.03 - 0.03 | 0.03 - 0.03 |
| Low: | 0.03 - 0.03 | 0.03 - 0.03 |
| Close: | 0.03 - 0.03 | 0.03 - 0.03 |
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Thu, 18 Apr 2024
Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering - GlobeNewswire
Tue, 05 Dec 2023
ForexTV | Small Business Resources - ForexTV.com
Mon, 18 Sep 2023
Histogen Announces Board Approval of Complete Liquidation and Dissolution - Yahoo Finance
Fri, 17 Mar 2023
Why Is Histogen (HSTO) Stock Up 37% Today? - InvestorPlace
Wed, 23 Mar 2022
Histogen Announces $4.75 Million Private Placement - Yahoo Finance
Mon, 08 Nov 2021
Histogen Announces CEO Transition - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.93e+006 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 55 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.192e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -70 % |
| Return on Assets (ttm) | 500 % |
| Return on Equity (ttm) | -53.9 % |
| Qtrly Rev. Growth | 19000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -106.1 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.02 |
| Dividend | 0 |
| Forward Dividend | 67030 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|